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Problem Hospitalized adult patients require more than one short peripheral catheter 
(SPC) to complete the prescribed intravenous (IV) therapy due to catheter failure and the 
practice of resiting. The purpose of this quality improvement initiative was to increase the 
rate of SPCs remaining in situ for the entire duration of the IV therapy for hospitalized 
adult patients.  
Methods Application of an engineered securement device (ESD), an educational program 
pertaining to modifiable risk factors, and changing the practice to removal upon clinical 
indication were methods utilized to reduce the number of SPC insertions and catheter 
failures. This study was conducted at a rural, Midwestern hospital using a convenience 
sample (N=405) and an observational, descriptive, cohort design in six phases between 
September 2019 and March 2020.  
Results Following the practice changes, there was a reduction of SPC replacement (24%), 
catheter failures (24% to 13%), SPCs per patient (M=2.9 to 2.2 p=.045), SPC insertions 
(4,000 per year), and zero SPC-related CRBSIs (0.26 per 1000 catheter days to 0.0) and a 
significant increase of SPCs remaining in situ (M=2.6 to 3.8 days; p=<.001), resulting in 
an estimated cost saving of at least $285,000. The results demonstrated the risk of failure 
significantly increased when inserted in the wrist (p=.007) and upper arm (p=.026) and 
significantly reduced when inserted in the forearm (p=0.39).  
Implications for Practice Study findings suggest the use of an ESD, promoting insertion 
in the forearm, avoidance of the wrist and upper arm, and the practice change to removal 
when clinically indicated.  
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Optimizing The Effectiveness Of Peripheral Intravenous Catheters  
Short peripheral intravenous catheter (SPC) insertion is the most common 
invasive procedure performed in the hospital (Flippo & Lee, 2011). The intention of a 
SPC insertion is for less than 6-days of intravenous (IV) therapy to infuse fluids, blood 
products, medications, and contrast media directly into the circulatory system. An SPC is 
defined as a catheter less than three inches (7.5 cm) inserted into and terminating in the 
peripheral vein of an extremity (O’Grady et al., 2011). There are 330 million SPCs sold 
annually in the U.S. (Hadaway, 2012). Furthermore, approximately 60 to 90% of 
admitted patients in an acute care hospital are prescribed IV therapy requiring an SPC 
(Helm, Klausner, Klemperer, Flint, & Huang, 2015). Interestingly, SPCs do not remain in 
situ for the entire duration of the prescribed IV therapy for hospitalized adult patients. 
Tan, Tai, Sim, and Ng (2016) found an average rate of 2.82 SPC insertions per patient 
admission with an average of 29% failing and 14.9% resited although functioning and 
asymptomatic. Hence, approximately 44% of adult patients require more than one 
catheter during their hospital stay to complete the prescribed IV therapy.  
A vascular access device (VAD) not remaining in situ for the entire intended 
duration due to complications is defined as a catheter failure. Undesirable high catheter 
failure rates between 16% and 70.7% causing a disruption in IV therapy has been 
reported in the literature (Rickard et al., 2018; Shears, 2006; Webster, Osborne, Rickard, 
& Marsh, 2019). SPCs have the highest rate of total complications compared to other 
VADs (Gunther et al., 2016). One failure initiates a cycle of catheter removal and 
reinsertion, further increasing the risk of failure with each subsequent attempt. 
Eventually, venous exhaustion occurs resulting in a more costly and higher risk VAD 
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being needed. Known VAD-related complications include phlebitis, infiltration, 
extravasation, infection, dislodgement, occlusion, and leakage with phlebitis and 
infiltration are reported as the most common causes of catheter failure (Helm et al., 
2015).  
Not only are patients receiving multiple SPCs due to catheter failure, but also 
because of the current practice of routine removal at timed intervals. Functioning, 
asymptomatic SPCs are being removed at designated intervals to insert a new catheter 
into another site, despite the Infusion Nurse Society (INS) recommendations. The INS 
recommended removal of a SPC when clinically indicated, meaning to remove when 
there are signs of VAD-related complications or the catheter is no longer needed (Gorski 
et al., 2016). In addition, the Centers for Disease Control and Prevention (CDC) updated 
the Guidelines for the Prevention of Intravascular Catheter-Related Infections to replace 
adult SPCs “no more frequently than every 72- to 96-hrs”, allowing for extended dwell 
times (cited in O’Grady et al., 2011 p. 16). This statement is incongruent with the CDC 
recommendation for replacement of SPCs in the pediatric population specifically stating 
to “replace peripheral catheters in children only when clinically indicated” (cited in 
O’Grady et al., 2011, p. 16). High-quality systemic reviews of randomized control trials 
(RCTs) have demonstrated no increased risk of phlebitis, infection, infiltration, or 
occlusion, and a significant cost savings when SPC sites are changed at routine intervals 
compared to removal when clinically indicated (Morrison & Holt, 2015; Webster et al., 
2019).  
 Currently, at a rural, Midwestern hospital, evaluating and changing SPC practices 
pertaining to stabilization and removal when clinically indicated have been identified as 
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an area of need. The purpose of this quality improvement (QI) initiative was to increase 
the rate of SPCs remaining in situ for the entire duration of the prescribed IV therapy for 
hospitalized adult patients. The aim of the project was to decrease SPC replacement by 
15% within 6-months. The primary outcome measures of interest were the rate of SPCs 
inserted per patient and catheter failures. Secondary outcomes measures included rates of 
catheter-related bloodstream infections (CRBSI), gauge, location, stabilization technique, 
removal reason, site signs and symptoms, length of stay (LOS), and days in situ. The 
questions for study were: In hospitalized adult patients aged 18-years and older requiring 
a SPC,  
1. how does the use of an engineered stabilization device compared to tape and a 
standard transparent dressing for stabilization affect the rate of SPC insertions and 
failures over 1-month intervals for a 6-month period?  
2. how does replacing the catheter only when clinically indicated compared to 
replacing the catheter every 96-hrs affect the rate of SPC insertions over 1-month 
intervals for a 6-month period? 
Literature Review 
The search engines used for this literature review included EBSCO, CINAHL, 
PubMed, and Google Scholar and the Cochrane Central Register of Controlled Trials 
(CENTRAL). The key search terms were securement, stabilization, dressing, clinically 
indicated, dwell, in situ, failure, and intravenous AND catheter AND peripheral. A total 
of 89 publications were initially obtained. A refined search with inclusion criteria were 
peer-reviewed, full-text, and English-language publications from 1999 through 2019. 
Publications were excluded if not human-research, adult population, or SPC study. 
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Additionally, an ancestry approach to some references was utilized. Eleven studies from 
2006 to 2018, addressing stabilization were selected including one systematic review, 
two integrative reviews, five RCTs, two prospective controlled cohort studies, and a 
retrospective cohort study. In addition, two systematic reviews from 2015 to 2019 
addressing removal when clinically indicated were selected. The following themes 
organized the literature review: catheter failure, stabilization, and removal practices.  
The high rate of SPC insertions per patient incurs unnecessary pain and anxiety 
while multiple attempts with each insertion further increases complications (Helm et al., 
2015). Van Loon et al. (2019) found an 81% first attempt success rate for adult 
hospitalized patients. The average rate per insertion is between 2.18 and 2.35 attempts 
(Hadaway, 2012). Multiple needlesticks cause frustration for the patient and clinician, 
especially when resiting a functioning catheter. Helm et al. (2015) synthesized RCTs 
from 1990 to 2014 finding ranges of: phlebitis (0.1% - 63.3%), infiltration (15.7% - 
33.8%), occlusion (2.5% - 32.7%), dislodgement (3.7% – 9.9%), and CRBSI (0.0% - 
0.44%). The various complication rates were dependent on inclusion and exclusion 
criteria, definitions, indicators, and populations in each study. 
Publications have shown significant correlations of specific modifiable risk 
factors (MRFs) contributing to catheter failure. A higher rate of phlebitis transpires with 
SPCs inserted in an area of flexion and high mobility such as the wrist, antecubital fossa 
(AC), hand (Wallis et al., 2014), or dominant extremity (Marsh et al., 2018). Large 
catheter diameters (Zhu, Wang, & Wen, 2016) increase the risk of phlebitis while a small 
catheter diameter increases the risk of dislodgement (Wallis et al., 2014) and infiltration 
(Marsh et al., 2018). Wallis et al. (2014) found upper arm SPCs increase the risk of 
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infiltration. Therefore, as demonstrated by Elia et al. (2011), upper arm SPCs have lower 
complication rates if longer than 5 cm (14%) compared to less than 5 cm (45%). The INS 
Infusion Therapy Standards of Practice recommended to (a) insert in the forearm and 
nondominant extremity, (b) avoid areas of flexion, (c) choose a 20- to 24-gauge for most 
IV therapies, (d) select a catheter of adequate length for deeper veins, and (e) consider a 
stabilization device (Gorski et al., 2016). DeRosenroll (2017) found educating clinicians 
about MRFs when selecting the location, laterality, and catheter gauge and length upon 
insertion will significantly affect outcomes including catheter failure. 
Stabilization devices may minimize catheter micromotion in the vein reducing 
premature catheter failure and complications (Fourie, 2015; Marsh et al., 2018). Multiple 
products have been promoted for SPC stabilization, each providing a unique method of 
securement and cost. Multiple terminologies and synonyms have been utilized among 
researchers, clinicians, and professional organizations causing confusion and challenges 
when reviewing evidence. To provide clarity, SPC stabilization devices were defined and 
categorized into six types: Tape is used in conjunction with gauze or a non-bordered 
transparent dressing (standard dressing [SD]); a bordered dressing (BD) is a bordered 
transparent dressing; an advanced securement dressing (ASD) is a bordered transparent 
dressing with an integrated device for stabilization; an engineered securement device 
(ESD) is a device with anchor points or clips for stabilization and used in conjunction 
with an SD or BD; and a tissue adhesive is an adhesive such as glue applied topically in 
conjunction with an SD or BD. Stabilization device products discussed in the research 
include but are not limited to ESDs (Grip-Lok™, StatLock™, VITAL-HOLD™, 
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Hubguard™), BDs (Advanced Tegaderm™, Securis™, Veni-Gard™), an ASD 
(Sorbaview SHIELD™), and a TA (Hystacryl™). 
The original stabilization technique, tape, has been found to increase the risk of 
contamination when retrieved from a pocket or adhered to a table prior to application 
(Morris & Tay, 2008). A large meta-analysis (N = 10,164) reported a new product 
established in 1996 (StatLock™) demonstrated reduced restart rates (67%) and a cost 
savings ($18,000 per hospital) compared to tape (Shears, 2006). Subsequently in 2006, 
the INS Standards stated to “consider an engineered stabilization device (ESD) to secure 
VADs” for the prevention of complications and dislodgement (Gorski et al., 2016, p. 73). 
StatLocks™ are also made for stabilizing other healthcare devices ranging from urinary 
catheters to drains. StatLocks™ continue to be the most commonly used VAD 
stabilization device globally. Since the introduction of the StatLock™, many types of 
stabilization devices have been manufactured, utilized, and researched. The Advanced 
Tegaderm™ with a winged catheter (WC) was compared to the StatLock™ with a 
standard catheter (SC) demonstrating similar failure rates and a cost savings of $2.57 per 
insertion with the Advanced Tegaderm™ (Delp & Hadaway, 2011). Studies comparing 
the Advanced Tegaderm™ with a SC or WC to a SD with a SC produced low-quality 
evidence (deRosenroll, 2017; Fourie, 2015; Jackson, 2012). Marsh, Webster, Flynn, and 
Mihala (2015) conducted a small RCT (N = 85) finding catheter failure rates highest with 
a SD (38%), BD (25%), ESD (22%), and TA (14%), respectively. TAs have shown to 
have antimicrobial properties inhibiting microbial growth (Simonova et al., 2012; 
Rickard et al., 2018), but caused skin tears, rashes, and blisters (Marsh, Webster, Flynn, 
et al., 2015). A comparison of the Advanced Tegaderm™ compared to a SD in a large  
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RCT (N = 628) demonstrated no difference in overall complications for patients (Gunther 
et al., 2016). A systematic review evaluated catheter failure identifying low-quality 
evidence that one product (SD, BD, or ESD) reduced complications or was superior 
(Marsh, Webster, Mihala, & Rickard, 2015). In 2018, a large RCT (N = 1807) comparing 
a BD, ESD, TA, and SD found no difference in failure rates and an actual cost savings 
with an SD (Rickard et al., 2018). Devries and Strimbu (2019) found over 3-years when 
using a BD with a WC there was, “difficulty maintaining a fully intact dressing” so the 
organization added a TA to significantly increase the rate of intact dressings from 55% to 
98% (Devries & Strimbu, 2019, p. 88).  
The 2016 INS Standards stated, “For peripheral catheters, consider two options 
for catheter stabilization” such as a WC with a BD or a SC with an ESD (cited in Gorski 
et al., 2016, p. 73). The INS Standards further reported a BD with a SC may increase in 
situ times, although further research was needed. The INS did not endorse one product, 
although recommendations to avoid tape, gauze, and SDs for securement due to 
ineffectiveness was specified (Gorski et al., 2016). This was interpreted as the reduction 
in failure rates was an affect of the catheter or securement device which must have an 
integrated stabilization, such as with an ASD, ESD, or WC.  
There are many limitations and minimal strengths of recent SPC stabilization 
technique research. While most studies had a significantly reliable sample size, three did 
not report the sampling method or size (deRosenroll, 2017; Jackson, 2012; Marsh, 
Webster, Flynn, et al., 2015) and one RCT had a small sample size (Marsh, Webster, & 
Flynn, et al., 2015). Several studies had limited generalization when conducted in a single 
center (Fourie, 2015; Gunther et al., 2016; Marsh, Webster, Flynn, et al., 2015; Marsh, 
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Webster, Mihala, et al., 2015) and when inserted in the forearm at an unusually high rate 
(80%) (Rickard et al., 2018). No research investigators were blinded due to the nature of 
the research; therefore, information bias was a potential in every study. There was a high 
risk of bias when researchers received monetary compensation or funding from the 
product manufacturer(s) (Bausone-Gazda et al., 2010; deRosenroll, 2017; Flippo & Lee, 
2011; Fourie, 2015; Jackson, 2012; Marsh, Webster, Mihala, et al., 2015). 
In 1996, the CDC Guidelines were updated to reflect evidence-based research 
reflecting adult SPCs were to be removed no more frequently than “every 72- to 96-hrs” 
(cited in O’Grady et al., 2011 p. 16). Since then, many high-quality studies evaluating 
SPC in situ times and outcomes have been conducted. The Australian Access Teaching 
and Research Group (AVATAR) conducted a systematic review to examine the effects of 
removing SPCs routinely versus when clinically indicated finding no difference of 
phlebitis when removed upon clinical indication (9%) versus routine removal (7.2%) 
(Webster, Osborne, Rickard, & Hall, 2010). Based on the emerging evidence, in 2011, 
the INS Standards recommended removing SPCs when clinically indicated (Gorski et al., 
2016). Furthermore, AVATAR conducted updated systematic reviews in 2010, 2013, 
2015, and 2019 with the last review finding no difference in the in incidence of CRBSI, 
thrombophlebitis, all-cause BSI, mortality, or pain (Webster, Osborne, Rickard, & Marsh, 
2019). In addition, there was moderate evidence of a $5 per patient cost savings with the 
clinically indicated group (Webster et al., 2019). Likewise, Morrison and Holt (2015) 
conducted a systematic review finding no difference in phlebitis or infection and reduced 
costs and time when practicing removal upon clinical indication.  
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In summary, recent research has not identified a superior SPC stabilization 
product to standardize practices which may contribute to the limitations of the SPC 
studies. This may be due to various study designs, additional variables affecting 
outcomes, and product research costs. Multiple interchangeable SPC insertion products 
have created a variation of combinations used outside and within organizations. There is 
a gap in the literature for large high-quality RCTs to evaluate the effects and cost of all 
stabilization techniques and to identify a superior device. Non-manufacturer grant 
funding may enable high-quality product research, potentially eliminating conflicts of 
interest and investigator bias. Furthermore, additional INS definitions of the different 
types of SPC stabilization devices and catheters is needed for researchers and clinicians 
to use consist language and have congruent interpretations of evidence when analyzing, 
disseminating, and implementing stabilization device research. Based on the evidence 
from the literature review, INS Standards, CDC Guidelines, the transition of practice 
from routine removal to when clinically indicated, and the addition of an evidence-based 
SPC stabilization technique has been recommended to reduce costs and prevent catheter 
failures.  
The Iowa Model of evidence-based practice to promote quality care, created by 
the University of Iowa Hospitals and Clinics, was utilized as the framework for this QI 
initiative (Iowa Model Collaborative, 2017). The Iowa Model employs a system’s 
perspective to guide clinical decisions when transitioning evidence into practice by 
identifying issues, researching solutions, and implementing changes (Iowa Model 
Collaborative, 2017). This model begins with the identification of the topic in question 
being a problem-focused trigger or a knowledge-focused trigger before the purpose or 
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question(s) for study are formulated. Once the problem, purpose, and practice question(s) 
are considered a priority for the organization, the QI process begins. 
Methods 
Design  
An observational, descriptive, cohort design was utilized. A retrospective medical 
record review was the primary method of data collection. The QI initiative was 
implemented in six phases over a 6-month period. Baseline data collection began 
September 15th, 2019 during Phase 1 (P1). A nursing education program regarding MRFs 
and implementation of an ESD was completed in the designated trial departments in 
Phase 2 (P2) starting November 19th, 2019. Patients with a documented or known 
contraindication or sensitivity to the ESD had tape and a SD or gauze applied as an 
alternative. A nursing education program regarding SPC care and maintenance and a 
practice change to clinically indicated was completed in the designated trial departments 
in Phase 3 (P3) beginning December 5th, 2019. In addition, simultaneously, applicable 
departments received the MRFs and ESD education for implementation hospital-wide. In 
Phase 4 (P4), education regarding SPC care and maintenance and a practice change to 
clinically indicated was implemented hospital-wide starting January 1st, 2020. The 
practice change to clinically indicated was implemented February 3rd, 2020 in Phase 5 
(P5). Finally, beginning March 5th, 2020 education and outcomes from the previous 
phases was reinforced in Phase 6 (P6).  
Setting  
 The setting was a rural, Midwestern hospital employing more than 1,500 
employees with approximately 127 outpatient clinic physicians affiliated with the 
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hospital across 24 specialty areas (Mercy, 2019a). Each year, there are over 38,000 
emergency department (ED) visits; 5,900 acute inpatient discharges; and 12,000 inpatient 
and outpatient surgeries performed at the hospital (Mercy, 2019a). This hospital is part of 
a multicenter healthcare organization with 30 acute care hospitals throughout four states 
in the Midwest region (Mercy 2019b). The hospital services about 180,000 patients living 
and working in the surrounding 17 cities. The county of origin has a population of 
slightly over 14,000 with a poverty rate (8.5%) below the state rate of 14.6% and with a 
majority race being white (93.3%), which is higher than the state rate of 79.8% (U.S. 
Census Bureau, n.d.).  
Approval Processes 
The Chief Nursing Officer (CNO) and President of the hospital approved the 
primary investigator (PI) to facilitate and initiate this QI initiative in collaboration with 
the Infection Control nurse. In addition, the university’s doctor of nursing practice (DNP) 
committee, institutional review board (IRB), and the hospital’s IRB granted approval. 
Benefits of this study included contributions to the decision-making about best practice 
for the hospital regarding SPCs. There was minimal risk to subjects as all patient 
identifiers of the data were removed and this was a retrospective analysis of nursing 
practice. 
Sample  
A convenience sample of SPCs inserted in adult patients admitted to the hospital 
was used in each phase. Inclusion criteria consisted of SPCs in adult patients 18-years of 
age or older admitted to the hospital, regardless of diagnosis or medications. Exclusion 
criteria consisted of SPCs inserted in pediatric patients 17-years of age or younger 
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admitted to the hospital, outpatients including clinic and ED patients who were not 
admitted, prehospital insertions, and labor and delivery inpatients.  
Data Collection/Analysis  
All data was acquired from an SPC audit instrument developed by the PI for QI. 
Demographic information was not collected. The rate of SPCs inserted per patient and 
catheter failure rates was obtained. Other data included SPC stabilization technique, 
gauge, location, removal reason, days in situ, site signs and symptoms, LOS, and CRBSI. 
The electronic medical record (EMR) provided six options for the removal reason: per 
policy, no longer indicated, site symptoms, per patient, per order, and observed not 
present. All data was stored on a password protected computer. Data collection included 
a visual site audit completed in a single day at least 4-days after the initiation of each 
phase and a chart audit was conducted in a single day at least 7-days following each 
visual site audit. Descriptive statistics and statistical analysis using chi-square, Fischer’s 
exact, binary logistic regression, ANOVA, and t-tests were conducted based on an alpha 
value of p < .05. Failure rates were defined as SPCs categorized as yes for the site signs 
and symptoms group or categorized as site symptoms for the removal reason group. The 
yes category included observations of erythema, swelling, pain, warmth/cool, and 
purulent drainage when observed during the visual audit. The blood category in the site 
signs and symptoms group was defined as observed dry or aqueous blood extending 
beyond the insertion site.   
Procedures  
This QI initiative practice interventions were systematically developed using a 
plan-do-study-act (PDSA) cycle plan and a timeline. A root cause analysis using a fish-
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bone diagram identified the cause and effects of multiple SPCs per patient (Appendix A). 
An evaluation of the hospital’s current practices and the system’s other four hospitals in a 
geographic location was undertaken including identification of products, policies, 
procedures, documentation, and reporting practices. For the past 2-years, the wound care 
specialist performed VAD audits with the assistance of wound care champions while 
completing quarterly wound prevalence audits. A pareto chart was devised based on the 
audit results (Appendix B). A formal meeting with key stakeholders was employed to 
engage the participants, present the plan, decide on a stabilization product and 
maintenance practices, and eliminate barriers. The key stakeholders assessed the 
stabilization technique options and decided to utilize the StatLockTM ESD for 
stabilization based on the literature review. Educational material was developed and 
delivered through multiple teaching strategies including a printed bulletin and a 5-minute 
roving demonstration. Content included MRFs affecting failure, application and removal 
of the ESD, maintenance, and removal procedures. Leadership announced the 
implementation dates and the product was stocked and available. A formal meeting was 
scheduled after each phase for key stakeholders to collaboratively evaluate and analyze 
the data, assess the implementation process, identify what was learned, review 
compliance, and decide to adopt, adapt, or abort the interventions.  
Results 
Between September 15th, 2019 and March 18th, 2020, there were 339 patients with 
one or more SPCs (N=405) secured with a SD (n=218) and an ESD (n=187). The SD 
category had failure in 19% (n=40) compared to 12% (n=23) in the ESD category. A chi-
square test of independence was conducted to examine whether failure and stabilization 
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technique were independent of each other. The results were not significant at the .05 level 
(χ
2
=2.80, df=1, p=.094), suggesting failure and stabilization technique were likely 
independent of one another.  
During P1 (baseline data), the mean number of SPCs per patient was 2.90 
(SD=2.11). Education pertaining to MRFs and stabilization techniques was given to 
inserters and the ESD was supplied after baseline data collection in P1. A two-tailed 
independent samples t-test was conducted to examine the rate of SPC per patient 
difference between the SD category (n=66) and the ESD category (n=82) during P2 and 
P3. The mean number of SPCs per patient for the SD category was 2.78 (SD=2.19) and 
was significantly higher than the mean for the ESD category 2.08 (SD=1.26) at the .05 
level (t=2.32, df=146, p=.021). The number of SPCs per patient was significantly 
different between stabilization techniques in P2 and P3, indicating the ESD was more 
stabilizing than the SD and resulted in a lower number of SPC restarts.  
Likewise, a two-tailed independent samples t-test was conducted to examine the 
difference between the number of SPCs per patient from P4 through P6 when the practice 
of clinically indicated was implemented hospital-wide. The mean number of SPCs per 
patient for the P4 category was 2.29 (SD=1.28) when compared to the P6 category 
(M=2.22, SD=1.32) and was not statistically significant at the .05 level (t=0.30, df=119, 
p=.767). There was essentially no difference in the number of SPCs per patient between 
P4 and P6 despite practicing removal only when clinically indicated.  
Next, a two-tailed independent samples t-test was conducted to examine if there 
was a difference in the mean number of SPCs per patient between P1 (n=49) and P6 
(n=82). The analysis was conducted to evaluate the effect of implementing the 
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cumulative SPC education and interventions hospital-wide. The P1 category (M=2.90, 
SD=2.11) had a higher rate of SPCs per patient compared to the P6 category (M=2.22, 
SD=1.32) and was statistically significant at the .05 level (t=2.03, df=102, p=.045). The 
number of SPCs per patient was significantly reduced in P6 following the cumulative 
interventions throughout the previous five phases. A trending decrease of SPCs per 
patient occurred after P1 (M=2.90, SD=2.11) and continued through P6 (M=2.37 
[SD=1.81]; 2.37 [1.76]; 2.29 [1.28]; 2.35 [2.16]; and 2.22 [1.32], respectively) (Appendix 
C). 
The mean days in situ was 3.11 (SD=2.35) for a total of 1,258 catheter days. The 
days in situ increased from P1 (M=2.63, SD= 1.48) to P6 (M=3.74, SD=3.20) correlating 
to an average of each SPC in situ for one additional day. An ANOVA was conducted to 
determine whether there was a significant difference of days in situ by stabilization 
technique. The results indicated no significant difference (F[1, 403] = 3.37, p = .067). 
The mean days in situ of the ESD category was 3.34 (SD=2.58) and was greater than the 
SD category (M=2.91, SD=2.12). An ANOVA with Tukey pairwise comparisons was 
conducted to determine whether there was a significant difference of days in situ by 
phase. The results indicated a significant difference (F[5, 399] = 5.09, p < .001) of days 
in situ among the phases with P5 and P6 significantly higher than P2. The highest rate of 
failures for the in situ group occurred in the zero to 1-day category (n=20, 20%). The 
failure rate in the 2- to 4-day category was n=33 (15%), the 5- to 8-day category was n=7 
(10%), and the 9- to 25-day category was n=3 (21%). Furthermore, 53 of 63 (84%) failed 
SPCs had failed when in situ less than 4-days. Of note, seven of 40 (18%) patients with a 
LOS 1-day or less required more than one SPC. 
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Analysis of site location demonstrated overall selection in the hand was 37 
(9.14%), wrist (n=37, 9.14%), forearm (n=147, 36.3%), antecubital ([AC], n=154, 
38.02%), and upper arm (n=28, 6.91%). An increase in forearm selection from P1 (n=16, 
33%) to P6 (n=38, 46%) was observed, although the most frequently observed location 
was AC (n=154, 38%). A chi-square test of independence was conducted to examine 
whether location and phase were independent of each other. The results were not 
significant at the .05 level (χ
2
=26.68, df=20, p=.145), suggesting location and phase were 
likely independent of one another. Therefore, there was not a significant change in the 
selection of location following the MRF educational program. A binary logistic 
regression was conducted to examine the effect of location on failure rates. The 
regression coefficient for the upper arm location was significant 
(B=1.15, OR=3.17, p=.026). Failure was likely in the upper arm at 217%. The regression 
coefficient for the wrist location was also significant (B=1.26, OR=3.52, p=.007). A 
failure was likely in the wrist at 252%.  A chi-square test of independence was conducted 
to examine if failure and location were independent of each other. The relationship 
between location and failure rate was statistically significant at the 0.05 level 
(χ2=10.08, df=4, p=.039). Hence, location was related to failure rates. SPCs in the 
forearm had a lower observed failure rate (n=14) than expected failure rate (n=22.62) 
compared to the hand (n=7, 5.6), wrist (n=10, 5.69), AC (n=24, 23.69), and upper arm 
(n=7, 4.31). In addition, the days in situ time was greater when in the forearm (M=3.44, 
SD=2.92). 
The catheter gauges used were 16 (n=3, 0.74%), 18 (n=57, 14.07%), 20 
(n=325, 80%), and 22 (n=20, 4.94%). The 20-gauge catheter was the most frequently 
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used catheter size with a steady increase in use from P1 (n=37, 76%) to P5 (n=50, 83%), 
but a decreased rate of use occurred in P6 (n=62, 76%).  Also, 14 of 57 (25%) 18-gauge 
catheters were inserted in the hand and wrist. The days in situ for each gauge catheter 
were 16 (M=3.33, SD=0.58), 18 (M=2.77, SD=1.76), 20 (M=3.13, SD=2.43), and 22 
(M=3.70, SD=2.64).  Interestingly, the mean days in situ was greatest for 22-gauge 
catheters (M=3.70, SD=2.64). A Fischer’s exact test was conducted to examine whether 
the rate of gauge and phase were independent of each other. The results were not 
significant at the .05 level (p=.300), suggesting the rate of gauge and phases were likely 
independent of one another. Therefore, there was not a significant change in the selection 
of gauge following the MRF educational program. A Fischer’s exact test was also 
conducted to examine whether the rate of gauge and failure were independent of each 
other. The results were not significant at the .05 level (p=.857), suggesting the rate of 
gauge and failure were likely independent of one another. A binary logistic regression 
was conducted to examine whether gauge had a significant effect on failure rates. The 
results were not significant (χ2=1.30, df=3, p=.728) suggesting gauge did not have an 
effect on failure.  
In the site signs and symptoms group, there was a low frequency in the yes 
category (n=7, 1.73%) and a high frequency in the blood category (n=130, 32.1%). The 
frequency in the blood category significantly decreased from P1 (n=30, 42%) to P6 
(n=14, 17%). A Fischer’s exact test was conducted to examine whether the rate of site 
signs and symptoms and phase were independent of each other. The results were 
significant at the .05 level (p=.012), suggesting the rate of site signs and symptoms and 
phases were likely not independent of one another. A lower than expected rate of the 
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blood category was observed in P3 (24[24.40]), P4 (17[21.19]), and P6 (12[26.32]) and a 
lower than expected rate of the yes category was observed in P2 (1[1.24]), P3 (1[1.31]), 
P4 (0[1.14]), and P5 (1[1.04]). 
The most frequently observed category in the reason for removal group was no 
longer indicated (n=145, 36%) compared to per policy (n=35, 9%), site symptoms (n=63, 
16%), per patient (n=17, 4%), per order (n=2, 1%), observed not present (n=6, 2%), not 
documented but removed at discharge (n=117, 29%), not documented thus removal 
unknown (n=20, 5%) (Appendix D). Unfortunately, 137 (34%) of the SPCs did not have 
a removal reason documented. A removal time was documented in 117 (85%) of the 137 
SPC’s within 2-hrs of being discharged; hence, the reason for removal due to discharge 
was assumed. The rate of the site symptoms category immediately decreased from 24% 
to 14% after implementing the ESD.  
The population’s mean LOS (M=4.77 days) (Appendix E) was greater compared 
to the organization’s reported mean from September 2019 to March 2020 (M=2.88 days). 
The difference was expected due to the exclusion of labor and delivery patients. There 
were 66 (16.3%) patients who had two SPCs concurrently, commonly due to 
incompatible or multiple IV infusions. In addition, 34 of 339 (10%) patients required a 
central IV catheter during their hospitalization. The number of central IV catheters 
inserted per patient decreased from P1 (n=6, 16%) to P6 (n=5, 8%) during the 6-month 
study period. A chi-square test of independence was conducted to examine whether the 
rate of central IVs and phase were independent of each other. The results were not 
significant at the .05 level (χ
2
=2.63, df=5, p=.757), suggesting the rate of central IVs and 
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phases were likely independent of one another. Finally, the hospital’s total number of 
CRBSI was zero during the 6-month period from P1 through P6. 
Discussion 
In hospitalized adult patients aged 18-years and older requiring a SPC, replacing 
the catheter only when clinically indicated compared to replacing the catheter every 96-
hrs did affect the rate of SPC insertions over 1-month intervals for a 6-month period. The 
P1 group had a higher rate of SPCs per patient compared to the P6 group (p=.045). The 
number of SPCs required per patient was significantly less in P6 after education of 
stabilization techniques and implementation of clinically indicated changing of an SPC 
throughout the previous five phases. A steady trending decrease of SPCs per patient 
occurred after P1 from an average 2.9 SPCs per patient to 2.37 SPCs per patient in P6.  
Regardless of the initial hospital policy of routine replacement at 96-hrs, some SPCs were 
remaining in situ longer than 96-hrs prior to implementing a formal practice change to 
remove only if clinically indicated. After the practice change, however, the rate of SPCs 
in situ after 96-hrs steadily increased from 8% (P1) to 29% (P6). This rate was 
comparable to the previously cumulative reported rates of SPCs resited plus SPCs 
remaining in despite organizational policies to resite (28.3%). The practice change from 
P3 to P6 when hospital-wide implementation occurred, provided a 20% reduction rate of 
at least one SPC for patient’s hospitalized between 5- and 8-days, and a 9% reduction rate 
of more than one SPC for patient’s hospitalized more than 8-days. Interestingly, one SPC 
stabilized with an ESD remained in situ for 25-days in P6, preventing an estimated six 
SPCs for one patient (Appendix F).  
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In hospitalized adult patients aged 18-years and older requiring a SPC, the use of 
an ESD compared to tape and a SD for stabilization affected the rate of SPC insertions 
and failures over 1-month intervals for a 6-month period. The baseline rate of 2.9 SPCs 
per patient during P1 was comparable to the rate previously reported but significantly 
higher than the 2.29 rate in P4 acquired before implementing the practice change to 
clinically indicated and the 2.22 rate acquired by the end of P6 (p=.05). When the ESD 
was introduced, the average number of SPCs per patient for the SD category (2.78) was 
significantly higher (p=.021) than for the ESD category (2.08). In contrast, implementing 
the practice change to clinically indicated did not result in a significant difference 
(p=.767) in the average number of SPCs per patient in P4 (2.29) compared to P6 (2.22). 
Despite statistical insignificance, the average number of SPCs per patient was reduced 
between P4 and P6. In fact, a downward trend in the number of SPCs per patient over 
time occurred when the ESD and practice change for removal only if clinically indicated 
were implemented. 
The number of SPCs stabilized with an ESD slightly increased during the study 
period. Stabilization selection was at the discretion of the insertor and the majority were 
inserted in the ED. Insertors were advised to utilize a SD on ED patients not admitted and 
surgical patients with less than an expected 24-hr LOS. The rate of failures decreased 
from 24% to 14% immediately after implementing the use of an ESD and MRF 
education. The failure rates were lower than previously reported failure rates. The failure 
rates are affected by documentation of the removal reason that is based on nursing 
selection and is not always complete. This may have contributed to the statistically 
insignificant association of stabilization and failure rates. The decreased failure rate, the 
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second highest rate of failure occurring in the 0- to 1-day in situ category (20%), and the 
rate of patients with a less than 24-hr LOS requiring more than one SPC (18%) support 
the use of an ESD for all SPCs including those intended to remain in situ less than 1-day. 
There is an opportunity to educate SPC insertors about the increased risk of failure with 
using a SD and to promote the usage of an ESD. Consideration for SPC policies to 
require an ESD for all inpatients is recommended.  
 While insertors select the location and gauge, further education is recommended 
to address the increased risk of failure when inserted in the upper arm (p=.026) and wrist 
(p=.007) and the statistically significant reduced risk of failure when inserted in the 
forearm (p=0.39). A high rate of insertions in the AC (38%) may have occurred due to a 
misunderstanding that a power injection procedure for computed tomography (CT) 
imaging studies must require an AC SPC, although this was addressed during P1 nursing 
education. Clarification within organizational policy was addressed to ensure adherence 
to the INS Standards and the American College of Radiology suggesting a large forearm 
vein was adequate. The result of the 22-gauge SPC having the highest in situ time (3.70 
days) was inconsistent with the previously reported higher risk of dislodgement 
infiltration, although consistent with the INS Standards. Midline catheters were not 
inserted before or during the study period and may have contributed to the rate of central 
IV catheters and upper arm SPCs. Midline catheter insertions are being considered for 
future implementation. However, there is not a designated vascular access team or nurse 
employed at the hospital and may be need to be a consideration. Currently, the critical 
care and ED nurses are consulted for difficult SPC insertions. Perhaps a vascular access 
nurse may enhance the insertion of midline catheters and prevent the need for central IV 
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catheters. The MRFs educational program most likely did not affect the number of SPCs 
per patient and the failure rates due to the rate of selecting gauge and location was 
insignificantly different among all phases.  
Infection is a potential complication from an SPC. While all SPCs had an attached 
extension, bonded needleless connectors were substituted with nonbonded needleless 
connectors to allow for changing the needleless connector prior to the practice change of 
removal when clinically indicated. During the study period, none of the SPCs remaining 
in situ beyond 7-days had documentation of the dressing, stabilization technique, and 
needleless connector being changed. While there is an opportunity for further education 
pertaining to documentation of SPC care and maintenance, astonishingly, the number of 
CRBSI was zero when compared to the previous fiscal year (0.26 per 1000 catheter 
days). Several factors may have contributed to the zero rate of CRBSI including a 
Hawthorne effect, reduction of SPC insertions, introduction of a no-touch antiseptic prep 
in the ESD kit, and reduced micromotion when using an ESD. The reduced CRBSI rates 
occurred prior to implementation of the interventions, therefore, are most likely the result 
of a Hawthorne effect. Regardless, removing a SPC only when clinically indicated did 
not increase the rate of CRBSI, and remarkably, produced no infections over a 6-month 
period. Further study over a longer period of time or a replication of this study is 
suggested. 
No SPC major adverse events, skin tears, or allergic reactions were reported 
during the study period. Additional SPC practices thought to negatively affect the 
outcomes were addressed throughout the phases of the project including: (a) correct use 
of an ESD; (b) avoidance of a restrictive dressing (e.g. CobanTM) or blood pressure cuff 
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on the SPC extremity; (c) netting (e.g. SurgilastTM) utilized to reduce accidental 
dislodgement; (d) securement of the extension set to the skin; (e) and the avoidance of 
tape on the catheter hub to prevent improper downward angle, kinking, and occlusion of 
the catheter when using an ESD. Thus, over a 6-month period, no additional adverse 
events were reported, suggesting intensive education with a careful, methodical approach 
to reducing the number of SPCs was effective. 
A major strength of this project was reliability as one individual collected all data. 
In addition, the PI did not receive monetary compensation from the organization or 
manufacturer, thus producing a low risk of bias. A limitation of this project was the 
potential overlapping of interventions during phases of the analysis. Recommendations 
for future research in SPC stabilization techniques include exploring the effect of the 
multiple interchangeable SPC products to identify a superior SPC product combination to 
standardize practices. High-quality product research funded by a non-manufacturer may 
potentially eliminate conflicts of interest and investigator bias. The effect of utilizing an 
ESD for SPCs intended to in situ for patients with a less than 24-hr LOS merits further 
investigation. Analysis of staff and patient satisfaction of SPC insertion, care, and 
maintenance may provide insight to opportunities for improvement. Furthermore, future 
research evaluating the insertor’s reason for location and gauge selection may identify 
effective strategies for increasing the use of MRFs to improve outcomes.  
Finally, the project aim to decrease SPC replacement by 15% within 6-months 
was exceeded as a reduction of 24% in SPC replacement occurred. A cost-benefit 
analysis demonstrated this QI initiative may have reduced the number of SPCs by 
approximately 4,000 per year. A total savings of at least $285,518 per year related to SPC 
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insertion reduction efforts may be realized, including the cost savings realized in the 
reduction of CRBSIs.  
Conclusion 
The combination of using an ESD and practice protocol of replacing SPCs only 
when clinically indicated resulted in a 24% reduction in the number of SPCs per patient 
and an 11% reduction in the number of catheter failures in a moderately sized, rural 
Midwestern hospital.  Furthermore, there were no reported cases of CRBSI during the 6-
month study period.  This project promoted safe clinical care, decreased the use of 
resources, reduced the disruption of therapy, prevented unnecessary venipunctures, and 
resulted in improved outcomes.  Since the insertion of an SPC is the most common, 
invasive procedure performed in the hospital, interventions to reduce complications 
should be a priority for any hospital organization.  




Bausone-Gazda, D., Lefaiver, C.A., & Walters, S. (2010). A randomized controlled trial 
to compare the complications of 2 peripheral intravenous catheter-stabilization 
systems. Journal of Infusion Nursing, 33(6), 371-384. 
doi:10.1097/NAN.0b013e3181f85be2 
Delp, J., & Hadaway, L. (2011). New product decisions – The Process and outcome for a 
community health system. Journal of the Association for Vascular Access, 16(2), 
74-84. doi:10.2309/java.16-2-4 
deRosenroll, A. (2017). Peripheral intravenous catheters: Improving outcomes through 
change in products, clinical practice and education. Vascular Access, 11(1), 7-12.  
Retrieved September 24th, 2019 from 
http://cvaa.info/Portals/0/Journal/Individual%20Articles/Articles%20with%20Co
ver%20Page/11-1%20deRosenroll.pdf 
Devries, M., & Strimbu, K. (2019). Short peripheral catheter performance following 
adoption of clinical indication removal. Journal of Infusion Nursing, 42(2), 81-90. 
doi:10.1097/NAN.0000000000000318 
Elia, F., Ferrari, G., Molino, P., Converso, M., Filippi, G.D., Milan, A., & Apra, F. 
(2012). Standard-length catheters vs long catheters in ultrasound-guided 
peripheral vein cannulation. American Journal of Emergency Medicine, 30, 712-
71. doi:10.1016/j.ajem.2011.04.019   
Flippo, P.L., & Lee, J. (2011). Clinical evaluation of the Sorbaview SHIELD securement 
device used on peripheral intravenous catheters in the acute care setting. The 
Journal of the Association for Vascular Access, 16(2), 1-7. doi:10.2309/java.16-2-
6 
PERIPHERAL INTRAVENOUS CATHETERS  
 
28 
Fourie, A. (2015). Peripheral intravenous catheter performance: Investigating peripheral 
intravenous catheter dwell times. Professional Nursing Today, 19(3), 7-11. 




Gorski, L., Hadaway, L. Hagle, M.E., McGoldrick, M., Orr, M., & Doellman, D. (2016). 
Infusion therapy standards of practice [Supplemental material]. Journal of 
Infusion Nursing, 39(1), S1-S159. 
Gunther, S.C., Schwebel, C., Hamidfar-Roy, R., Bonadona, A., Lugosi, M. Ara-
Somohano, C. … Timsit, J. (2016). Complications of intravascular catheters in 
ICU: Definitions, incidence, and severity: A randomized controlled trial 
comparing usual transparent dressings versus new-generation dressings (the 
ADVANCED study). Intensive Care Medicine, 42, 1753-1765. 
doi:10.1007/s00134-016-4582-2 
Hadaway, L. (2012). Short peripheral intravenous catheters and infection. Journal of 
Infusion Nursing, 35(4), 230-240. doi:10.1097/NAN.0b013e31825af099 
Helm, R.E., Klausner, J.D., Klemperer, J.D., Flint, L.M., & Huang, E. (2015). Accepted 
but unacceptable: Peripheral IV catheter failure. Infusion Nurses Society, 38(3), 
189-203. doi:10.1097/NAN.0000000000000100 
Iowa Model Collaborative. (2017). Iowa model of evidence-based practice: Revisions 
and validation. Worldviews on Evidence-Based Nursing, 14(3), 175-182. 
doi:10.1111/wvn.1222 
PERIPHERAL INTRAVENOUS CATHETERS  
 
29 
Jackson, A. (2012). Retrospective comparative audit of two peripheral IV securement 
dressings. British Journal of Nursing, 21(2), 16-20. 
doi:10.12968/bjon.2012.21.Sup1.S10 
Marsh, N., Webster, J., Flynn, J., Mihala, G., Hewer, B., Fraser, J., & Rickard, C.M. 
(2015). Securement methods for peripheral venous catheters to prevent failure: A 
randomized controlled pilot trial. The Journal of Vascular Access, 16(3), 237-244. 
doi:10.5301/jva.50000348 
Marsh, N., Webster, J., Mihala, G., & Rickard, C.M. (2015). Devices and dressings to 
secure peripheral venous catheters to prevent complications. The Cochrane 
Database of Systematic Reviews, 6, 1-56. doi:10.1002/14651858.CD011070.pub2 
Mercy. (2019a). Mercy Hospital Washington Quick Facts. Retrieved September 3, 2019 
from https://www.mercy.net/newsroom/mercy-hospital-washington-quick-facts/ 
Mercy. (2019b). Mercy Quick Facts. Retrieved September 3, 2019 from 
https://www.mercy.net/newsroom/mercy-quick-facts/ 
Morris, W., & Tey, M.H. (2008). Strategies for preventing peripheral intravenous cannula 
infection [Supplement]. British Journal of Nursing, 17(19), 14-21 
doi:10.12968/bjon.2008.17.Sup8.31470 
Morrison, K., Holt, K. (2015). The effectiveness of clinically indicated replacement of 
peripheral intravenous catheters: an evidence review with implications for clinical 
practice. Worldviews on Evidence-Based Nursing, 12(4). 187-198. 
doi:10.1111/wvn.12102. 
O’Grady, N.P., Alexander, M., Burns, L.A., Dellinger, P., Garland, J., Heard, S.O., … 
The Healthcare Infection Control Practices Advisory Committee. (2011). 
PERIPHERAL INTRAVENOUS CATHETERS  
 
30 
Guidelines for the prevention of intravascular catheter-related infections. Clinical 
Infectious Disease: An Official Publication of the Infectious Disease Society of 
America, 52(9), 1-83. doi:10.1093/cid/cir257 
Rickard, C.M., Marsh, N., Webster J., Runnegar, N., Larsen, E., McGrail, M.R., … 
Playford, E.G. (2018). Dressings and securements for the prevention of 
intravenous catheter failure in adults (SAVE): A pragmatic, randomized 
controlled, superiority trial. The Lancet, 392, 419-430. doi:10.1016/S0140-
6736(18)31380-1 
Shears, G.J., (2006). Summary of product trials for 10,164 patients: Comparing an 
intravenous stabilizing device to tape. Journal of Infusion Nursing, 29(4), 225-
231. 
Simonova, G., Rickard, C.M., Dunster, K.R., Smyth, D.J., McMillan, D., & Fraser, J.F. 
(2012). Cyanoacrylate tissue adhesives - effective securement technique for 
intravascular catheters: In vitro testing of safety and feasibility. Anesthesia and 
Intensive Care, 40(3), 460-466. doi:10.1177/0310057X1204000311 
Tan, Y.H.G., Tai, W.L.S., Sim, C., & Ng, H.L.I. (2016). Optimizing peripheral venous 
catheter usage in the general inpatient ward: A prospective observational study. 
Journal of Clinical Nursing, 26, 133-139. doi:10.1111/jocn.13451  
U.S. Census Bureau. (n.d.). Quick Facts: Franklin County, Missouri; Missouri; 
Washington city, MO. Retrieved September 3, 2019 
from https://www.census.gov/quickfacts/fact/table/franklincountymissouri,MO,w
ashingtoncitymissouri/PST045218 
PERIPHERAL INTRAVENOUS CATHETERS  
 
31 
van Loon, F.H.J., van Hooff, L.W.E., de Boer, H.D., Koopman, S.S.H.A., Buise, M.P., 
Korsten, H.H.M., …Bouwman, A.R.A. (2019). Journal of Clinical Medicine, 8, 
144. doi:10.3390/jcm8020144  
Wallis, M.C., McGrail, M., Webster, J., Marsh, N., Gowardman, J., Playford, G., & 
Rickard, C.M. (2014). Risk factors for peripheral intravenous catheter failure: A 
multivariate analysis of data from a randomized controlled trial. Infection Control 
and Hospital Epidemiology, 35(1), 63-68. doi:10.1086/674398 
Webster, J., Osborne, S., Rickard, C.M., & Hall, J. (2010). Clinically-indicated 
replacement versus routine replacement of peripheral venous catheters. The 
Cochrane Database of Systematic Reviews, 3, 1-39. 
doi:10.1002/14651858.CD007798.pub2 
Webster, J., Osborne, S., Rickard, C.M., & Marsh, N. (2019). Clinically-indicated 
replacement versus routine replacement of peripheral venous catheters. The 
Cochrane Database of Systematic Reviews, 1, 1-55. 
doi:10.1002/14651858.CD007798.pub5 
Zhu, A., Wang, T., & Wen, S. (2016). Peripheral intravenous catheters in situ for more 
than 96h in adults: What factors affect removal? International Journal of Nursing 

























Figure 2.  Frequency of Causes for Multiple SPCs per Patient 
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Appendix D  
Table 1. Summary Results of Phases 
 
 
Note. Due to rounding, percentages may not equal 100%. 
 
Variable Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6 n %
Sample Size 49 (12%) 72 (18%) 76 (19%) 66 (16%) 60 (15%) 82 (20%) 405 100 
Stabilization Technique
    SD 49 (100%)38 (53%) 44 (58%) 26 (39%) 28 (47%) 33 (40%) 218 53.83
    ESD 0 (0%) 34 (47%) 32 (42%) 40 (61%) 32 (53%) 49 (60%) 187 46.17
Dwell
    0-1 day 12 (24%) 28 (39%) 20 (26%) 11 (17%) 11 (18%) 17 (21%) 99 24.4
    2-4 days 33 (67%) 37 (51%) 43 (57%) 39 (59%) 29 (48%) 42 (51%) 233 55.1
    5-8 days 4 (8%) 6 (8%) 13 (17%) 16 (24%) 14 (23%) 16 (20%) 69 17
    9-25 days 0 (0%) 1 (1%) 0 (0%) 0 (0%) 6 (10%) 7 (9%) 14 3.5
Central IV 6 (16%) 5 (8%) 7 (11%) 7 (13%) 4 (8%) 5 (8%) 34 10.03
> 1 SPC Coexisting 10 (20%) 9 (12%) 11 (14%) 10 (15%) 9 (15%) 17 (21%) 66 16.3
Location
    Hand 5 (10%) 2 (3%) 13 (17%) 5 (8%) 6 (10%) 6 (7%) 37 9.14
    Wrist 5 (10%) 8 (11%) 7 (9%) 4 (6%) 4 (7%) 9 (11%) 37 9.14
    Forearm 16 (33%) 22 (31%) 29 (38%) 25 (38%) 17 (28%) 38 (46%) 147 36.3
    Antecubital 17 (35%) 36 (50%) 23 (30%) 28 (42%) 25 (42%) 25 (30%) 154 38.02
    Upper Arm 5 (10%) 4 (6%) 4 (5%) 3 (5%) 8 (13%) 4 (5%) 28 6.91
    External Jugular 1 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 0.25
    Axillary 0 (0%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 1 0.25
Gauge
    16 1 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2%) 3 0.74
    18 10 (20%) 9 (12%) 11 (14%) 7 (11%) 5 (8%) 15 (18%) 57 14.07
    20 37 (76%) 62 (86%) 60 (79%) 54 (82%) 50 (83%) 62 (76%) 325 80.25
    22 1 (2%) 1 (1%) 5 (7%) 5 (8%) 5 (8%) 3 (4%) 20 4.94
    WDL 41 (57%) 51 (67%) 27 (55%) 49 (74%) 35 (58%) 65 (79%) 268 66.17
    Blood 30 (42%) 24 (32%) 21 (43%) 17 (26%) 24 (40%) 14 (17%) 130 32.1
    Sign or Symptom 1 (1%) 1 (1%) 1 (2%) 0 (0%) 1 (2%) 3 (4%) 7 1.73
    Per Policy 4 (8%) 10 (14%) 12 (16%) 4 (6%) 0 (0%) 5 (6%) 35 8.64
    Site Symptoms 12 (24%) 10 (14%) 11 (14%) 8 (12%) 11 (18%) 11 (13%) 63 15.56
    Per Patient 4 (8%) 2 (3%) 1 (1%) 3 (5%) 4 (7%) 3 (4%) 17 4.2
    Per Order 0 (0%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 2 0.49
    Not Present 1 (2%) 1 (1%) 0 (0%) 0 (0%) 1 (2%) 3 (4%) 6 1.48
    Not Indicated 16 (33%) 19 (26%) 18 (24%) 30 (45%) 22 (37%) 40 (49%) 145 35.8
    No doc-At DC 12 (24%) 20 (28%) 29 (38%) 17 (26%) 20 (33%) 19 (23%) 117 28.89
    No doc-Unknown 0 (0%) 9 (12%) 4 (5%) 4 (6%) 2 (3%) 1 (1%) 20 4.94
Failure 12 (24%) 10 (14%) 11 (14%) 8 (12%) 11 (18%) 11 (13%) 63 15.56
Site Signs and Symptoms
Removal Reason





Table 2. Summary Results for Number of SPCs, In Situ, Location, Gauge, and LOS 
 
Variable M SD n SEM Min Max Skewness Kurtosis 
SPCs per patient                 
    P1 2.90 2.11 39 0.34 1.00 9.00 1.46 1.57 
    P2 2.37 1.81 63 0.23 1.00 12.00 2.88 11.53 
    P3 2.37 1.76 65 0.22 1.00 10.00 1.92 4.53 
    P4 2.29 1.28 56 0.17 1.00 5.00 0.78 -0.41 
    P5 2.35 2.16 51 0.30 1.00 15.00 4.23 21.46 
    P6 2.22 1.32 65 0.16 1.00 7.00 1.34 2.00 
    Total 2.38 1.73 339 0.09 1.00 15.00 2.71 11.99 
In Situ (days)                 
    P1 2.63 1.48 49 0.21 0.00 7.00 0.81 0.57 
    P2 2.25 1.77 72 0.21 0.00 10.00 1.55 3.99 
    P3 2.89 1.76 76 0.20 0.00 8.00 0.74 0.03 
    P4 3.17 1.78 66 0.22 0.00 8.00 0.64 -0.26 
    P5 3.85 2.92 60 0.38 0.00 13.00 1.35 1.62 
    P6 3.74 3.20 82 0.35 0.00 22.00 2.62 11.25 
    Total 3.11 2.35 405 0.12 0.00 22.00 2.30 11.23 
         
    SD 2.91 2.12 218 0.14 0.00 13.00 1.58 3.68 
    ESD 3.34 2.58 187 0.19 0.00 22.00 2.66 14.01 
         
    Hand 2.89 1.58 37 0.26 0.00 7.00 0.70 0.13 
    Wrist 2.46 2.29 37 0.38 0.00 9.00 1.60 1.85 
    Forearm 3.44 2.92 147 0.24 0.00 22.00 2.50 10.70 
    Antecubital 2.94 1.92 154 0.15 0.00 12.00 1.33 3.06 
    Upper Arm 3.29 1.86 28 0.35 0.00 8.00 0.66 0.15 
         
    16-G 3.33 0.58 3 0.33 3.00 4.00 0.71 -1.50 
    18-G 2.77 1.76 57 0.23 0.00 7.00 0.84 -0.09 
    20-G 3.13 2.43 325 0.13 0.00 22.00 2.46 12.11 
    22-G 3.70 2.64 20 0.59 0.00 9.00 0.60 -0.58 
LOS (days)                 
    P1 4.69 2.82 39 0.45 0.00 12.00 0.75 -0.10 
    P2 4.32 2.94 63 0.37 1.00 14.00 1.33 1.46 
    P3 4.52 3.52 65 0.44 0.00 16.00 1.35 1.83 
    P4 4.79 3.39 56 0.45 0.00 17.00 1.33 2.04 
    P5 5.08 4.10 51 0.57 0.00 19.00 1.34 1.46 
    P6 5.25 6.34 65 0.79 1.00 47.00 4.85 28.05 
    Total 4.77 4.11 339 0.22 0.00 47.00 4.08 33.26 
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